Article info

Download PDFPDF

Original research
Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis

Authors

  1. Correspondence to Dr Shunsuke Mori; mori.shunsuke.ra{at}mail.hosp.go.jp
View Full Text

Citation

Mori S, Urata Y, Yoshitama T, et al
Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis

Publication history

  • Received January 27, 2021
  • Revision received April 13, 2021
  • Accepted April 22, 2021
  • First published May 6, 2021.
Online issue publication 
May 06, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.